THE ROLE OF HIV-1 VPU IN THE REGULATION OF CD40

HIV-1 VPU 在 CD40 调节中的作用

基本信息

  • 批准号:
    8173207
  • 负责人:
  • 金额:
    $ 15.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-05-01 至 2011-04-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall goal of this project is to understand the role of the HIV-1 protein Vpu in HIV pathogenesis. The original aim was to understand how Vpu modulates expression of the cytokine receptor CD40. Our studies showed that Vpu's effect on CD40 was due to downstream modulation of other pathways. We thus performed proteomics to identify novel cellular proteins affected by Vpu in a beta TrCP-dependent manner, and identified BST-2 as a significant Vpu target. This was important, since BST-2, was recently identified as a host antiviral factor that restricts the release of HIV from infected cells. BST-2 was renamed tetherin and independent studies confirmed our finding that Vpu antagonizes BST-2. We thus refocused our project goals to investigate the mechanisms and biological consequences of Vpu-mediated BST-2 downregulation and have made significant progress in this regards. We found that Vpu interacts with and targets BST-2 for degradation by an endosomal/lysosomal pathway and that beta TrCP is required for degradation and have published this work. We have made additional progress in the following areas i) mapping Vpu regions necessary for overcoming BST-2 restriction of viral egress; ii) characterizing the role of ubiquitin in Vpu-mediated BST-2 degradation; iii) identifying BST-2 binding partners involved in virion tethering or acting as adapters for Vpu function. This progress has allowed us submit a new R01 application "Characterization of Vpu-medicated Degradation of BST-2". Our BST-2 reagents were also used in collaborative work to examine BST-2 antagonism by the KSHV K5 protein that is now published.
这个子项目是众多研究子项目之一

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ASHLEE V. MOSES其他文献

ASHLEE V. MOSES的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ASHLEE V. MOSES', 18)}}的其他基金

KSHV Manipulates Host Iron Metabolism and Ferroptotic Cell Death Pathways, Creating Novel Vulnerability Points for Therapeutic Intervention.
KSHV 操纵宿主铁代谢和铁死亡细胞死亡途径,为治疗干预创造新的脆弱点。
  • 批准号:
    10155452
  • 财政年份:
    2020
  • 资助金额:
    $ 15.22万
  • 项目类别:
KSHV Manipulates Host Iron Metabolism and Ferroptotic Cell Death Pathways, Creating Novel Vulnerability Points for Therapeutic Intervention.
KSHV 操纵宿主铁代谢和铁死亡细胞死亡途径,为治疗干预创造新的脆弱点。
  • 批准号:
    10079716
  • 财政年份:
    2020
  • 资助金额:
    $ 15.22万
  • 项目类别:
KSHV Manipulates Host Iron Metabolism and Ferroptotic Cell Death Pathways, Creating Novel Vulnerability Points for Therapeutic Intervention.
KSHV 操纵宿主铁代谢和铁死亡细胞死亡途径,为治疗干预创造新的脆弱点。
  • 批准号:
    10400156
  • 财政年份:
    2020
  • 资助金额:
    $ 15.22万
  • 项目类别:
KSHV Manipulates Host Iron Metabolism and Ferroptotic Cell Death Pathways, Creating Novel Vulnerability Points for Therapeutic Intervention.
KSHV 操纵宿主铁代谢和铁死亡细胞死亡途径,为治疗干预创造新的脆弱点。
  • 批准号:
    10617677
  • 财政年份:
    2020
  • 资助金额:
    $ 15.22万
  • 项目类别:
Heme oxygenase-1 as a tumor factor and therapeutic target for Kaposi sarcoma
血红素加氧酶-1 作为肿瘤因子和卡波西肉瘤的治疗靶点
  • 批准号:
    9248335
  • 财政年份:
    2015
  • 资助金额:
    $ 15.22万
  • 项目类别:
Development Research Plan
发展研究计划
  • 批准号:
    8234057
  • 财政年份:
    2011
  • 资助金额:
    $ 15.22万
  • 项目类别:
MECHANISMS OF KSHV-INDUCED CELLULAR TRANSFORMATION
KSHV 诱导的细胞转化机制
  • 批准号:
    8173190
  • 财政年份:
    2010
  • 资助金额:
    $ 15.22万
  • 项目类别:
Characterization of Vpu-mediated degradation of BST-2
Vpu 介导的 BST-2 降解的表征
  • 批准号:
    8646860
  • 财政年份:
    2010
  • 资助金额:
    $ 15.22万
  • 项目类别:
Characterization of Vpu-mediated degradation of BST-2
Vpu 介导的 BST-2 降解的表征
  • 批准号:
    8458052
  • 财政年份:
    2010
  • 资助金额:
    $ 15.22万
  • 项目类别:
Characterization of Vpu-mediated degradation of BST-2
Vpu 介导的 BST-2 降解的表征
  • 批准号:
    8065911
  • 财政年份:
    2010
  • 资助金额:
    $ 15.22万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 15.22万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 15.22万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 15.22万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 15.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 15.22万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 15.22万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 15.22万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 15.22万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 15.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 15.22万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了